1. Field of the Invention
The present invention relates to medical devices, and more particularly to micro-electrical-mechanical systems (MEMS) using electric charge and conjugated polymers to engage biological tissue.
2. Related Art
Use of conjugated polymers for use in biomedical applications is a relatively new but rapidly developing area. Certain conjugated polymers undergo dimensional changes when ions transfer into or out of the polymer. The unique properties of conjugated polymers have prompted research into using them as actuators for use as micro-muscles, tiny steerable micro-catheters, endoscopes that can be guided inside blood vessels or along the spinal cord, and micro-fluidic devices.
Electroactive polymers, also referred to as “conjugated polymers” or “conductive polymers” or “conducting polymers,” are characterized by their ability to change shape in response to electrical stimulation, such as applying a voltage potential or current or electric field at the polymer. Conducting polymers typically have a conjugated backbone and increase electrical conductivity under oxidation or reduction. Some common conjugated polymers are polyaniline, polypyrrole (PPy) and polyacetylene. These materials are typically semi-conductors in their pure form. Oxidation or reduction promotes higher conductivity, an electron charge imbalance, and ion flow into or out of the material in order to balance charge. Ions, or dopants, may enter the polymer if ions are present in the immediate vicinity of the polymer, such as a conductive electrolyte medium. On the other hand, if ions are already present in the polymer when it is oxidized or reduced, they may exit the polymer in the presence of voltage. In some conjugated polymers, expansion (or contraction) is due to ion insertion (or deletion) between chains. The dimensional change may be more pronounced where the transferred ion is bound with larger molecules. In other polymers interchain repulsion may be the dominant effect.
The conjugated polymer may be coupled with a substrate material to form a controllable actuator. The observed magnitude of the dimensional change of a conjugated polymer and actuation force will vary depending on the composition of the conjugated polymer and the substrate on which it is deposited, their dimensions and thickness, polymer deposition and manufacturing/preparation techniques, the ion environment adjacent to the polymer, the voltage applied, and the number of actuation cycles. Conjugated polymers are a potentially good candidate for micro-scale actuation of biomedical devices because they may be integrated and fabricated with an underlying substrate and larger MEMS system, actuation typically requires low voltage (+/−1 V), and they can be made from biologically stable materials. Moreover, a MEMS biomedical system employing a conjugated polymer can be controllably actuated on a micro (less than 2 mm) scale.
Neural interface devices pose problems that may benefit from a conjugated polymer actuation system. Microelectrodes placed in the vicinity of nerves may function as nerve stimulators, sensors, or both. A challenge in this area is in creating and maintaining a healthy biotic interface between the targeted nerves and the device. The body tends to react to an implanted device by treating it as a foreign object, and will typically initiate an immune response and surround the device with encapsulating cells. The body's immune response may cascade, causing chronic encapsulation and irreversible neural cell damage at the biotic interface. Such reactions tend to degrade the signal to noise ratio (SNR) of signals received by or transmitted from the neural device. SNR also degrades as distance increases between the electrode interface and the target neural site. Where the device is configured to transmit signals to neural tissue, increasing the voltage of the signals to reach the targeted nerves can lead to other deleterious effects, including unwanted stimulation of surrounding tissue. Where the device is functioning as a receiver of neural signals, close proximity and good SNR are especially desirable. Further, it is observed that larger devices cause more biological trauma along the insertion path and at the target site, exacerbating the body's immune response.
Securing a neural interface to the target area presents further challenges. Even if initially well-placed, if the interface is insecurely attached to the biological tissue it may move or dislodge entirely, resulting in faulty signal communication and degraded SNR. Attachment requirements may differ depending on the area of the body in which the interface operates. Securing an interface within an organ, e.g., a deep-brain implant, will require different attachment techniques than securing a device to the surface of an organ, e.g., electrocorticography (ECOG) electrodes on the brain, or retinal implants on the retina. Attachment requirements to a peripheral nerve, e.g., along an arm, may differ from organ attachment techniques, or attachment along the spinal cord. Common to all such applications, however, is the desirability of securing the interface close to the targeted neural tissue.
US 20100016957 (Jager et al.) involves using electroactive conjugated polymers in biomedical devices. Jager discloses embodiments which control microdelivery of drugs and act as micro surgical tools, such as micro-forceps. Jager also discloses using electroactive polymers to deliver micro quantities of drugs to neural tissue, and to bind or splice torn or cut neural tissue. However, Jager does not disclose using conductive polymers to place microelectrodes in communication with neural tissue, or implantable, intra-tissue articulating portions that penetrate biological tissue.
US 20100268055 (Jung, et al.) discloses a MEMS neural electrode that may be articulated from a substrate. However, Jung does not disclose use of electroactive polymers to actuate the articulated portion, but rather at least two layered materials having different thermal expansion coefficients; Jung's device is pivotally actuated, for example, by changing the ambient temperature around the device.
US 20100268312 (Wallace et al.) discloses an electroactive polymer actuator coupled with a plurality of electrodes engageable with neural tissue in the cochlea portion of the ear. However, Wallace's system does not disclose articulating portions that pivot from a base portion, and in any case is many times larger than the micro-scale neural interface system disclosed by the present invention.
It would be useful to have a MEMS system having minimal size yet controllable tissue engagement, enabling a precise interface with targeted biological tissue such as neural tissue. It would be useful if the system comprised multiple actuators that could be collectively or independently moved, with multiple independently operable interface areas. Such devices would, for example, facilitate placement of electrodes proximate to the intended neural tissue, and further permit selective stimulation of proximal neural tissue. Further, such a system could be configured to grasp biological tissue and secure the device at the target area, further improving SNR and reducing or eliminating the need for sutures, adhesives, or other attachment techniques.
A biological tissue interface system is disclosed which employs an electroactive polymer actuator to pivot a tissue interface portion. Such a system may be particularly well adapted to interface with neural tissue. In one embodiment, the system comprises a base portion having a base substrate, an articulating portion having a proximal end attached to the base portion and a free distal end, and an actuator operably coupled to the articulating portion, driven by a conjugated polymer that changes dimension in response to an applied voltage potential, an electric current, electric field, or electric charge. The polymer applies a force to pivot the articulating portion, relative to the base portion, from a first position to a second position. The articulating portion has a tissue interface located at its distal end. In neural interface applications, the distal end may have at least one microelectrode or polymer conductor engageable with neural tissue.
These and other features and advantages of the present invention will become more readily appreciated when considered in connection with the following detailed description and appended drawings, wherein:
After first briefly describing conjugated polymers and the challenges of interfacing with neural tissue, this description will focus on an exemplar embodiment for providing a microelectrode site with a projection that can be actuated via a conjugated polymer from the surface of a base substrate to reduce the distance to a neural interface target. This feature may improve the neural interface by optimizing the electrode-tissue distance or by distancing the electrode site from the base substrate when favored. Subsequently, other examples of MEMS devices utilizing polymer actuators to engage with neural and other biological tissue will be described.
Electroactive polymers, also referred to as “conjugated polymers” or “conductive polymers” or “conducting polymers,” are characterized by their ability to change shape in response to electrical stimulation. They typically have a conjugated backbone and the ability to increase electrical conductivity under oxidation or reduction. Some common electroactive polymers are polypyrrole (PPy), polyaniline, and polyacetylene. These materials are typically semi-conductors in their pure form. However, upon oxidation or reduction of the polymer, conductivity is increased. The oxidation or reduction leads to a charge imbalance that, in turn, results in a flow of ions into or out of the material in order to balance charge. These ions, or dopants, enter the polymer from an ionically conductive electrolyte medium that is coupled to the polymer surface. If ions are already present in the polymer when it is oxidized or reduced, they may exit the polymer.
Conjugated polymer performance is highly dependent on its synthesis and the medium in which it is employed. Each new blend or application needs to be characterized to ensure that it performs as expected. PPy is substantially biocompatible, requires low power to undergo dimensional change, and has other features that enable fabrication according to the current invention. PPy is characterized by alternating single and double bonds along the polymer backbone. A large counter anion such as dodecylbenzenesulfonate (DBS) may be used to polymerize PPy. The DBS becomes embedded into the polymer matrix leaving only the influx and efflux of hydrated cations in the solution as the main mechanism of actuation.
Where the conjugated polymer is present in an environment having ions with hydration shells, such as human body tissue, a mass movement of ions and their hydration shells moving in and out of the polymer matrix causes change in polymer volume. Oxidation, or removal of electrons, can be electrochemically achieved by the application of a sufficiently positive voltage potential or electric charge (e.g. current and/or electric field). To maintain charge neutrality after oxidation, the polymer seeks to incorporate negatively charged ions to compensate for these positive charges on the polymer backbone. Smaller cations, being more electronegative and surrounded by larger hydration shells, produce greater force and displacement in the polymer during reduction. Smaller anions, such as Cl—, are also known to participate in charge balancing in the PPy, but don't have as large of an effect on volume change. Divalent cations may enter the polymer when present but are known to be less mobile because of their stronger binding forces.
If a negative voltage potential is applied to the polymer in the presence of ions, reduction of the polymer occurs, and the polymer seeks to shed negatively charged ions. Thus the conjugated polymer component in the presence of electrical or electronic stimulation can effectuate an actuation, effectively a reversible volume change in the polymer matrix and/or ion flux with the surrounding electrolyte medium. This behavior of the conjugated polymer can be exploited to bend a substrate on which the polymer is placed. In addition to PPy, any conjugated polymer that exhibits contractile or expanding properties may be used within the scope of the invention. Polyaniline is another example of such a usable conjugated polymer.
From an energy and safety standpoint, it may be preferable to configure the devices of the present invention such that the electroactive polymers expand where no potential is applied (i.e., under steady state conditions) and constrict upon the application of an appropriate voltage, or vice versa depending on the application. The polymer composition and its preparation can often be modified to achieve the desired steady-state configuration. Given the small size of the actuators, the embodiments presented herein contemplate using the body environment as the electrolyte source, with ionic species and their species concentrations present in the biological tissue environment.
The disclosed invention may be particularly useful to interface electric signaling systems (adapted either to emit or receive signals) with neural tissue. An effective interface for neural stimulation and recording are strongly dependent on the physical proximity of the electrode to the neurons targeted. Both recording quality and stimulation therapy are subject to the proximity of the electrode to the intended target, where attenuation is caused by the diffusivity of the signal as a function of distance in the application medium. Signal attenuation within the brain has been shown to be inversely proportional to the distance squared. Unfortunately the inflammatory response to the devices also frequently disrupts normal neuronal density. Likewise, in the eye, gaps that occur between the retina and stimulating electrode array are detrimental to efficacy of the therapy. Similarly, within cochlear implants the separation distance between the electrode array and the neural receptors along the cochlear wall increases the stimulus levels required which limits the electrode density and consequently decreases the frequency resolution of hearing.
In order to mitigate the immune response, anti-inflammatory coatings such as dexamethasone and substrates made from parylene and polyethylene glycol have been used to make a variety of devices more biocompatible. Conjugated polymers and carbon coatings have been used to reduce electrode site impedances while increasing charge transfer for stimulation. Also, attempts of seeding growth factors and stem cells on the probe to promote new neuron growth have also been studied as methods to bridge the electrode interface gap. Nevertheless, mitigating the underlying immune response remains a challenge.
Turning to the drawings,
Turning to
As noted above, the conjugated polymer 30 may be fabricated and conditioned such that it is coplanar with the base portion 10 in its first “steady state” position, i.e., without an electrical charge or voltage potential applied to conjugated polymer 30. As used in this application, an applied “electric charge” includes an applied voltage potential, an applied electric current, and/or an applied electric field. Alternatively, conjugated polymer 30 could be fabricated such that in its first steady state position it is pivoted away from substrate 10. Thus the expanded state of polymer 30, shown in
Turning to
The lower pair of articulating portions 12 in
Depending on the dimensions of the articulating portion and the desired application, a plurality of conductive portions may be placed on a single articulating portion 12.
A retina application is shown in
The disclosed device and method can actuate an arm (the articulating portion) carrying a conductive surface such as a microfabricated electrode (either a sensor or transmitter) that can be manipulated and moved in vivo on the biological tissue/nerve, either implanted into the tissue or at the tissue surface, to maintain or optimize contact. Applications may include enhancing grid electrodes such as ECOG electrodes, retinal implants, peripheral neural applications, and cuff electrodes. The common desire in such applications is to make contact between a microelectrode site and the targeted nerve/tissue. By adding the ability to adjust the contact distance and pressure, the desired application may be enhanced by improving the signal to noise ratio and decreasing the amplitude for stimulation therapy, thereby reducing deleterious effects.
Some researchers are investigating neurons mechanically twitching as a result of stimulus. Similarly, conjugated polymers are known for their impedance changes due to strain. The articulating portions could thus also function as a pressure sensor. A pressure on the articulating portion could translate to a stress on the conjugated polymer to which it is coupled, causing a change in its impedance. Such a device could thus be adapted to detect tissue motion and fluctuation both at the microlevel or grossly.
The MEMS device may be microfabricated. For example, specific regions of a microfabricated base substrate may be embedded or coated with a conjugated polymer. This can be done in a variety of ways. One method is to mechanically fabricate the base substrate and the articulating portion substrate, then apply a conjugated polymer to a portion of the articulating portion substrate (i.e. by physical vapor deposition, electrochemical deposition, or chemical deposition) thereby creating a bilayer articulating portion. A number of materials may be used for the base portion and articulating portion substrates. Traditional MEMS materials such as silicon and/or flexible polymers may be used for the base portion substrate. For the articulating portion substrate, the same materials may be used, preferably having more elasticity than the base portion substrate. In addition, resorbable substrate materials such as polyethylene glycol may be used, in whole or in part, on either substrate portion. Microfabrication techniques are known to those skilled in the art. By way of example only, a device might be formed using two different thicknesses of parylene for the base and articulating portion substrates. In such example, the parylene substrate may be coated with a thin layer of metal, such as Cr/Au on the order of hundreds of angstroms) for polymerization. Continuing with the same example, a layer of PPy(DBS) may then be galvanostatically polymerized on the Au layer of the articulating substrate with a deposition current density preferably of 1 mA/cm2 or less in a solution of 0.1 M pyrrole and 0.1 M DBS using a galvano/potentiostat. An Ag—Ag/Cl reference electrode and porous carbon counter electrode may be used. Further information on MEMS microfabrication methods and techniques may be found at Smela, E., “Microfabrication of PPy microactuators and other conjugated polymer devices,” Journal of Micromechanics and Microengineering, vol. 9, no. 1, pp. 1-18 (1999), which is incorporated by reference in its entirety.
Conjugated polymer actuators cause substrate deflection from the mechanical strain induced from the polymer swelling and shrinking. Variables determining the features that can be actuated successfully include substrate material properties, substrate dimensions, and actuator strain and dimensions. Variables affecting actuation performance include bilayer actuation force, resulting in deflection, and substrate buckling due to insertion forces, and biological environment, including ambient ionic concentrations. Therefore, the combination of the substrate bending stiffness and insertion and buckling forces should be considered while designing actuators tailored for the specific applications. When provided with substrate dimensions, actuators for electrode projections can be designed to fulfill a variety of application specifications. Conjugated polymer actuation strain is subject to several variables including polymer and dopant combinations, polymerization settings, actuating environment, redox speed, and actuator dimensions. Although the strain from these actuators are small in comparison with traditional actuation modalities, the typical deflections needed in neural interfacing applications is in the millimeter and micron scale and the power required to actuate the disclosed devices are favorable over other actuation modalities.
The specifications for electrode projections can be determined by the desired spread from the base substrate. Projections may be made from various substrate materials and can design their dimensions to satisfy targeted specifications. Application or fabrication considerations that impose limitations on the substrate material or particular dimensions can still vary the remaining independent variables including actuator thickness to produce more force to achieve their desired deflections.
This work introduces,the feasibility and mechanical considerations of conjugated polymers for use in a variety of neural interfacing applications. Electrode sites with individual projections can be actuated from the surface of their underlying substrate to reduce their distance to their interfacing target. This feature may improve the neural interface by optimizing the electrode-tissue distance or by distancing the electrode site from the larger substrate when favored. In another embodiment, the invention may be favorably employed as a neural shunt. In another embodiment, the invention may be favorably employed as a biological tissue grasping device. In another embodiment, the invention may be favorably employed to steer current/voltage to neural tissue. In another embodiment, the invention may be favorably employed in the bottom of a microelectrode well for in vitro use to engage with biological tissue and/or cells.
The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the invention; all such modifications are intended to be included within the scope of the invention.
This application claims priority to Provisional Patent Application No. 61/449,913 filed Mar. 7, 2011, the entire disclosure of which is hereby incorporated by reference and relied upon.
Pursuant to 35 U.S.C. §202(c), the United States government may have an interest in the invention described herein, which was made in part with funding from the Center for Neural Communication Technology, a P41 Resource Center funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB, P41 EB002030), and supported by the National Institutes of Health (NIH). This work was also supported by the Department of Defense Multidisciplinary University Research Initiative (MURI) program administered by the Army Research Office under grant W911NF0610218.
Number | Date | Country | |
---|---|---|---|
61449913 | Mar 2011 | US |